A Comprehensive Review on Caesalpinia bonduc (L.) Roxb. (Fevernut/ Kakachoo): Taxonomy, Ethnopharmacology, Phytochemistry, Pharmacological Activities, and Future Perspectives

Medicinal plants occupy a central position in global healthcare, supplying approximately 25% of all currently used pharmaceutical drugs ¹³. The growing incidence of antimicrobial resistance, adverse effects of synthetic drugs, and escalating costs of modern therapeutics have intensified interest in plant-based medicine ^1,2. Among the large pharmacopoeia of traditional medicinal plants, Caesalpinia bonduc (L.) Roxb.—popularly known in English as Fevernut, Nicker bean, or Physic nut, and in Hindi as Katkaranj or Kakachoo—stands out as a plant of exceptional medicinal versatility ^1,5.

The genus Caesalpinia is vast, encompassing more than 500 species distributed across tropical and subtropical biomes worldwide ². Within this genus, C. bonduc has attracted the most sustained scientific interest due to its prolific use across indigenous medicine systems of India, Africa, Southeast Asia, and Latin America ^1,2,5. In Indian traditional medicine, the plant has been described in classical Ayurvedic texts under the Sanskrit names Latakaranja and Putikaranja and has been used to treat intermittent fevers, diabetes mellitus, inflammation, worm infestations, skin diseases, hydrocele, and reproductive disorders ^1,2.

Phytochemical investigations have revealed a rich repertoire of secondary metabolites, particularly cassane- and norcassane-type diterpenoids, which appear to be the principal bioactive scaffold ^3,4. In vitro, ex vivo, and in vivo studies have validated numerous traditional claims ^{6,7,8,9,10,14}. However, systematic reviews collating the full breadth of pharmacological data alongside taxonomy, pharmacognosy, and safety information remain relatively sparse, especially those incorporating literature published after 2020 ^2,5. This comprehensive review addresses that gap by synthesizing data from PubMed, Scopus, Web of Science, ScienceDirect, Google Scholar, and ResearchGate up to early 2025.

Figure 1: Spiny seed pods of Caesalpinia bonduc (L.) Roxb. on the branch, showing the characteristic prickly pericarp.

2. TAXONOMY AND NOMENCLATURE

The accepted scientific name of the plant according to current botanical classification is Guilandina bonduc L. (World Flora Online, 2023) ¹⁵; however, the names Caesalpinia bonduc (L.) Roxb. and Caesalpinia bonducella (L.) Fleming remain widely used in the pharmacological literature and are treated here as synonyms ^1,2.

2.1 Taxonomic Classification

Table 1: Taxonomic classification of Caesalpinia bonduc [16, 19].

2.2 Synonyms

Accepted synonyms include: Caesalpinia bonducella (L.) Fleming; Caesalpinia crista Linn.; Guilandina bonduc L.; Bonduc majus Medik.; Guilandina bonducella L.; Guilandina gemina Lour.; and Caesalpinia jayabo Maza, among others ^2,15.

2.3 Vernacular Names

C. bonduc is known by a wide range of common names across the languages and regions where it is traditionally used, including Fevernut, Nicker bean, and Physic nut in English; Katkaranj and Kakachoo in Hindi; Latakaranja in Sanskrit; and corresponding vernacular names in Bengali, Tamil, Telugu, Malayalam, Kannada, Oriya, Arabic, Persian, and French, among other languages ^1,2.

3. BOTANICAL DESCRIPTION AND MORPHOLOGY

Caesalpinia bonduc is a large, straggling, perennial, prickly shrub or woody climber that can reach up to 10 m in height when supported ². The species name 'bonducella' is derived from the Arabic word bonduce, meaning 'little ball', an allusion to the globular shape of the seeds ⁵.

3.1 Stem and Branches

The stem is woody, green to grey, longitudinally striated, and heavily armed with recurved, hooked, and straight yellow-brown prickles approximately 0.3 cm long ². Young branches are densely grey-tomentose (finely downy). The thorns are present on both the rachis and branches, facilitating the plant's climbing habit ^2,5.

3.2 Leaves

Leaves are large, alternate, bipinnate, 30–90 cm long, with 3–8 pairs of pinnae ². Each pinna bears 3–4 pairs of opposite or sub-opposite leaflets. Leaflets are oblong to ovate, 2.5–5 cm × 1.5–3 cm, mucronate at apex, and slightly hairy on both surfaces. Stipules are subulate and caducous. The rachis itself is thorny ¹⁶.

3.3 Flowers

Flowers are bright yellow, bisexual, arranged in dense axillary or terminal racemes of 15–30 cm length ². Each flower has 5 petals, the upper petal being smaller than the others with reddish streaks at the base. Sepals are 5, reddish-brown on the inner surface. Stamens are 10, free, with hairy filaments. Flowering season: primarily August to October ⁵.

3.4 Fruits and Seeds

Fruits are oblong leguminous pods, 5–9 cm × 3.5–5 cm, covered with dense, stiff, yellowish prickles ². Each pod contains 1–2 seeds. Seeds (the most medicinally prized part) are ovoid to globose, 1.5–2.5 cm in diameter, hard, lead-grey to dark grey in colour with a smooth, lustrous surface ⁵. The seed coat is extremely hard and durable, enabling seeds to float in seawater for extended periods—an adaptation facilitating long-range ocean dispersal ². Fruiting season: December to March.

3.5 Roots

Root system is well-developed and woody ⁵. Root bark is thin, yellowish-grey, and bitter in taste. Roots are used medicinally in Ayurvedic preparations for fever and liver disorders ^1,2.

4. GEOGRAPHICAL DISTRIBUTION AND ECOLOGY

Caesalpinia bonduc exhibits a pantropical distribution, occurring across tropical and subtropical regions of Asia, Africa, the Americas, and the Pacific Islands ^1,2,5. In India, it is abundantly found in the Andaman and Nicobar Islands, Eastern Ghats, coastal Maharashtra, Goa, Kerala, Tamil Nadu, Karnataka, and Odisha. Beyond India, it is recorded in Sri Lanka, Bangladesh, Myanmar, Vietnam, China, Thailand, Indonesia, Australia, Caribbean islands, and parts of tropical Africa ².

Ecologically, the plant thrives in moist deciduous forests, evergreen forests, scrub jungles, coastal thickets, and disturbed habitats ⁵. It shows considerable tolerance to saline coastal environments and is frequently found on seashores, riverbanks, forest margins, and hedges ². The plant grows best at altitudes below 1,000 m, in sandy to loamy soils with moderate rainfall (1,000–3,000 mm/year) and full to partial sunlight ².

5. ETHNOPHARMACOLOGY AND TRADITIONAL USES

The ethnomedicinal use of C. bonduc spans centuries and multiple traditional medical systems ^1,2. The earliest documented references appear in classical Ayurvedic texts including the Charaka Samhita and Sushruta Samhita, where the plant is described as a febrifuge, anthelmintic, and anti-inflammatory agent ¹. Traditional documentation has been consistently reaffirmed by ethnobotanical surveys conducted across India and other tropical regions up to the present day ^2,5.

5.1 Ayurveda

In Ayurveda, Latakaranja is classified as having tikta (bitter) and kashaya (astringent) rasa, laghu and ruksha properties, and ushna veerya (hot potency) ¹. It is prescribed as a kaphavata pacifying drug. Traditional indications include jwara (fever), shwasa (asthma), kasa (cough), krimi (helminthiasis), udara (abdominal disorders), and arsha (haemorrhoids) ^1,2. Formulations include Karanjadi churna and Latakaranjadi kwatha ¹.

5.2 Siddha System

In Siddha medicine, practiced predominantly in Tamil Nadu, the plant is known as Kazharchi ¹. Seed kernel preparations are used as kashayam (decoctions) to treat recurring fevers, diabetes, and liver diseases ^1,2. The seeds are also roasted and administered as a general tonic ¹.

5.3 Unani System

In Unani medicine, the nuts and leaves are classified for their Muha'lil-e-waram (anti-inflammatory), Musakkin-e-alam (antipyretic), Musaffi-i-Dam (blood-purifying), and Dafi-i-Tashannuj (anticonvulsant) properties ^1,2. Key conditions treated include Humma (seasonal fevers), Diq al-Nafas (bronchial asthma), Su'al-o-Surfa (bronchitis), Istisqa Ziqqi (ascites), Qarw Ma'i (hydrocele), and Dhat al-Janb (pleurisy) ¹.

5.4 Folk and Tribal Medicine

Table 2: Traditional uses of various parts of Caesalpinia bonduc [11, 15, 16].

6. PHARMACOGNOSTIC EVALUATION

6.1 Macroscopic Characters

Seeds: Ovoid to spherical, 1.5–2.5 cm diameter; surface smooth, glossy, lead-grey; extremely hard testa; cotyledons pale yellow, oily; distinct raphe visible ^5,16. Odour: faint, characteristic; taste: bitter and astringent. Leaves: Alternate, bipinnate; leaflets 2–5 cm, oblong, slightly hairy; mid-rib prominent; odour faint; taste slightly bitter ¹⁶.

6.2 Microscopic Characters

Seed transverse section reveals a thick, lignified testa composed of palisade-like macrosclereid cells (malpighian cells) forming the outermost layer, followed by a layer of hourglass cells (osteoscleroids) ^5,16. The cotyledonary parenchyma is filled with protein bodies and oil globules. Vascular bundles are collateral type. Calcium oxalate crystals (prism type) are present in the seed coat parenchyma. Leaf section shows dorsiventral lamina, anomocytic stomata, unicellular covering trichomes, and a prominent midrib with collateral vascular bundle ¹⁶.

6.3 Physicochemical Standards

Table 3: Physicochemical parameters for C. bonduc seed kernel and leaves [11, 17].

6.4 Phytochemical Screening

Preliminary phytochemical screening of various solvent extracts of C. bonduc seeds consistently reveals the presence of: alkaloids (Dragendorff's test +), flavonoids (alkaline reagent +), saponins (froth test +), tannins (FeCl3 +), phytosterols (Liebermann–Burchard +), glycosides (Keller–Kiliani +), terpenoids (Salkowski +), phenolic compounds (+), fixed oils (+), proteins and amino acids (+) ^5,12,16,17. Starch and reducing sugars are also detectable in some extracts ¹².

7. PHYTOCHEMISTRY

More than 97 phytoconstituents have been isolated and structurally characterized from various parts of C. bonduc ^3,4,5. The chemical diversity of this species is remarkable, spanning multiple biosynthetic classes. Seeds (particularly the kernel) are the most extensively studied plant part ^1,5.

7.1 Cassane and Norcassane Diterpenoids

This class represents the chemotaxonomic marker of the genus and the primary bioactive scaffold ³. Cassane diterpenoids isolated from seeds, stems, and roots include: caesalpinins A–P, caesalmins A–K, taepeenins A–L, neocaesalpins B, C, D, and H, and caesalpinianone ^3,4. Norcassane diterpenoids include norcaesalpinins, nortaepeenins A and B, and related compounds ⁴. These diterpenes feature a characteristic furanyl ring system (furanoditerpenes) that is linked to their cytotoxic and anti-inflammatory properties ^3,5.

7.2 Alkaloids

Alkaloids identified include bonducin (the principal bitter principle), bonducellin, and several uncharacterized minor alkaloids ^1,3. Bonducin is a diterpene-related bitter substance responsible for significant antidiabetic and antipyretic activity ^7,12.

7.3 Flavonoids and Homoisoflavonoids

The leaves and young twigs are particularly rich in flavonoids ¹⁷. Isolated compounds include: apigenin, luteolin, quercetin, kaempferol, quercetin-3-methyl ether, and several isoflavone glycosides ^11,17. Legumes (unripe pods) have yielded naringenin and kaempferol ¹⁸.

7.4 Phenolic Acids

Leaves contain significant quantities of phenolic acids: caffeic acid, chlorogenic acid, p-coumaric acid, ferulic acid, and gallic acid ^11,17,19. These contribute to antioxidant and anti-inflammatory activities ^11,19.

7.5 Steroids and Phytosterols

β-sitosterol is the predominant phytosterol, along with stigmasterol, campesterol, and cholesterol in minor amounts ^3,5. These compounds contribute to anti-inflammatory, anticancer, and hypocholesterolaemic activities ^1,5.

7.6 Fatty Acids and Seed Oil

Fixed oil content of seed kernels ranges from 15–18% (w/w) ⁵. Major fatty acids include linoleic acid (C18:2), oleic acid (C18:1), palmitic acid (C16:0), and stearic acid (C18:0) ⁵. The seed oil has been evaluated for anti-inflammatory and antifungal properties ^1,5.

7.7 Other Constituents

Additional constituents isolated include: citrulline (an amino acid), homoisoflavonoid sphytosterin, saponins (responsible for the frothy aqueous extract), tannins (gallotannins), polysaccharides from the seed gum, and fixed and volatile oils in minor proportions ^3,4,5.

9. STRUCTURE–ACTIVITY RELATIONSHIPS (SAR)

The cassane diterpenoid scaffold of C. bonduc offers rich opportunities for SAR analysis ³. Key structural determinants of bioactivity are:

Furanoditerpene skeleton: The fused furan ring attached to the cassane diterpene backbone is critical for cytotoxic and antimalarial activity ^3,5. Removal or saturation of the furanyl moiety dramatically reduces potency. Hydroxylation at specific ring positions (C-7, C-11) enhances anti-inflammatory and antidiabetic activity ³.

Flavonoid hydroxylation pattern: The catechol B-ring (3',4'-dihydroxyl) present in luteolin and quercetin confers superior antioxidant and anti-inflammatory activity compared to monohydroxyl flavones like apigenin ¹¹. Glycosylation at C-3 modulates bioavailability and receptor binding ^11,17.

Phenolic acid conjugation: Ester-linked phenolic acids (chlorogenic acid = caffeoylquinic acid) demonstrate stronger antioxidant activity than their free acid counterparts, attributed to the synergistic effect of the quinic acid moiety enhancing electron delocalization ^11,19.

10. TOXICOLOGICAL PROFILE

Despite extensive pre-clinical pharmacological data, comprehensive, systematically conducted toxicological assessment of C. bonduc remains one of the principal gaps in the literature ².

10.1 Acute Toxicity

The LD50 of seed extracts in mice via the oral route is generally reported as >2,000 mg/kg body weight (OECD 423 limit test), classifying the plant as Category 5 (low acute toxicity) by GHS classification ^2,5. Intraperitoneal administration yields lower LD50 values (~800–1,200 mg/kg). No significant gross pathological changes were noted in surviving animals at sub-lethal doses ⁵.

10.2 Sub-chronic and Chronic Toxicity

28-day repeated dose studies in Wistar rats at doses of 250–1,000 mg/kg demonstrated no significant changes in haematological parameters, serum biochemistry (liver enzymes, creatinine, urea), organ weight ratios, or histopathology of liver, kidney, spleen, and testes at doses up to 500 mg/kg ^2,5. Mild hepatic changes were observed at 1,000 mg/kg in some studies, warranting caution at very high doses ².

10.3 Reproductive and Developmental Toxicity

Anti-implantation and abortifacient activity of C. bonduc seed extracts at higher doses has been documented in rats, attributed to antiestrogenic activity ^2,5. This constitutes a significant safety concern: the plant is contraindicated in pregnancy and use during breastfeeding should be avoided pending further safety data ².

10.4 Genotoxicity

Limited Ames test data suggest absence of direct mutagenicity at sub-cytotoxic concentrations ². However, adequate in vivo genotoxicity studies (micronucleus test, comet assay) with characterized extracts are not yet available in peer-reviewed literature. This represents a regulatory gap for any clinical development pathway ².

11. MODERN FORMULATIONS AND NANO-FORMULATION APPROACHES

Beyond classical Ayurvedic formulations, recent research has explored modern delivery systems to improve the bioavailability and efficacy of C. bonduc phytoconstituents, which are limited by poor water solubility (diterpenoids) and rapid first-pass metabolism (flavonoids) ^2,5.

Nanoparticle formulations: Silver nanoparticles (AgNPs) green-synthesized using C. bonducella leaf extract demonstrate enhanced antimicrobial and larvicidal efficacy compared to the extract alone ². Polymeric nanoparticles (PLGA-based) encapsulating seed diterpenoid fractions show improved cytotoxicity and sustained release profiles in cancer cell line studies ⁵.

Phytosomes: Complexation of flavonoid fractions with phosphatidylcholine (phytosome technology) has been investigated to enhance oral bioavailability, with promising results in antioxidant and hepatoprotective assays ⁵.

Standardized extracts: HPLC/HPTLC-based standardized dry extracts normalized to bonducellin or total cassane diterpenoid content are under development for use in clinical trials, enabling dose precision and reproducibility across batches ^2,16.

12. REGULATORY STATUS AND QUALITY CONTROL

Caesalpinia bonduc seed (Latakaranja) is listed in the Ayurvedic Pharmacopoeia of India (API), Volume I, which provides official monograph standards for identity, purity, and strength ¹. The drug is also listed in the Indian Herbal Pharmacopoeia (IHP) and several state-level formularies. Internationally, the plant is referenced in the WHO Monographs on Selected Medicinal Plants Series; however, full regulatory approval as a new botanical drug (under CDSCO/AYUSH guidelines for Ayurvedic drugs) remains in the classical use category rather than as a modern phytopharmaceutical ^1,13.

For publication and export purposes, the plant drug must comply with: (1) API physicochemical limits; (2) WHO good agricultural and collection practices (GACP) ¹³; (3) WHO/ICH guidelines on heavy metals (Pb ≤10 ppm, As ≤3 ppm, Cd ≤0.3 ppm, Hg ≤0.2 ppm); (4) Aflatoxin limits (B1+B2+G1+G2 ≤4 ppb); and (5) pesticide residue limits as per European Pharmacopoeia ¹³.

13. RESEARCH GAPS AND FUTURE PERSPECTIVES

Despite decades of pre-clinical research, several critical gaps limit the translation of C. bonduc from traditional use to modern therapeutic application ^1,2,5:

1. Clinical trials: No randomized controlled clinical trials (RCTs) have been conducted for any pharmacological indication ². Well-designed Phase I/II trials for antidiabetic and antimalarial activity, using standardized, characterized extracts, are urgently needed ^2,5.

2. Mechanism elucidation: Detailed molecular mechanisms—target identification, receptor binding studies, signal transduction pathways—remain incomplete for most pharmacological activities ². Network pharmacology and molecular docking approaches should be systematically applied ².

3. Comprehensive toxicology: Sub-chronic, chronic, teratogenicity, and genotoxicity studies conforming to OECD guidelines using characterized extracts are lacking ². Herb–drug interaction studies are essentially absent ².

4. Bioavailability and pharmacokinetics: ADME profiles of key compounds (bonducin, caesalpinin, major diterpenoids) in relevant animal models and ultimately humans are unavailable, hindering rational dose selection ^2,5.

5. Isolation of novel compounds: Advanced analytical techniques (LC-MS/MS, NMR, X-ray crystallography) should be applied to less-studied plant parts (flowers, roots, fresh latex) to identify additional bioactive compounds ^3,4.

6. Conservation and sustainability: Given increasing interest in the plant, wild-harvesting pressures are rising ⁵. Tissue culture-based propagation, sustainable cultivation practices, and quality standardization across growing regions warrant attention ^2,5.

7. Nanotechnology-based delivery: Nano-encapsulation of poorly soluble diterpenoids to improve bioavailability, along with targeted delivery systems for anticancer applications, represents a high-priority research direction ^2,5.

14. CONCLUSION

Caesalpinia bonduc (L.) Roxb. is a pharmacologically exceptional medicinal plant deeply embedded in the traditional medicine systems of tropical Asia ^1,2. Its chemical complexity—anchored by a unique suite of cassane and norcassane diterpenoids alongside diverse flavonoids, phenolic acids, and sterols—underpins a remarkably broad spectrum of biological activities: antidiabetic, antimalarial, anti-inflammatory, antimicrobial, antifungal, antioxidant, anticancer, hepatoprotective, anticonvulsant, immunomodulatory, antifilarial, and antiestrogenic, among others ^{3,5,6,7,8,9,10,11,12,14}.

The convergence of traditional ethnopharmacological evidence and modern pre-clinical validation strongly supports the potential of C. bonduc as a source of novel therapeutic agents, particularly for antidiabetic, anticancer, and antimalarial drug development ^2,5. Cassane furanoditerpenes, in particular, represent an underexplored scaffold for medicinal chemistry optimization ³.

However, the journey from bench to bedside remains incomplete ². The critical next steps—systematic clinical trials, comprehensive toxicological studies, pharmacokinetic characterization, and mechanistic molecular pharmacology—are necessary before C. bonduc-derived preparations can be endorsed for mainstream therapeutic use ². With appropriate scientific rigour and investment, this remarkable fevernut has the potential to yield valuable contributions to modern medicine in the coming decade ^2,5.

ABBREVIATIONS

• ABTS — 2,2'-Azino-bis(3-ethylbenzothiazoline-6-sulfonic acid)
• ADME — Absorption, Distribution, Metabolism, Excretion
• API — Ayurvedic Pharmacopoeia of India
• COX — Cyclooxygenase
• DPPH — 2,2-Diphenyl-1-picrylhydrazyl
• DTH — Delayed-Type Hypersensitivity
• EECS — Ethanolic Extract of Caesalpinia bonduc Seeds
• FRAP — Ferric Reducing Antioxidant Power
• GACP — Good Agricultural and Collection Practices
• GHS — Globally Harmonized System (of Classification and Labelling of Chemicals)
• HPTLC — High-Performance Thin-Layer Chromatography
• IC50 — Inhibitory Concentration (50%)
• LD50 — Lethal Dose (50%)
• MES — Maximal Electroshock Seizure
• MIC — Minimum Inhibitory Concentration
• PCOS — Polycystic Ovary Syndrome
• PTZ — Pentylenetetrazole
• RCT — Randomized Controlled Trial
• ROS — Reactive Oxygen Species
• SAR — Structure–Activity Relationship
• SERM — Selective Estrogen Receptor Modulator
• SOD — Superoxide Dismutase
• SRBC — Sheep Red Blood Cells
• STZ — Streptozotocin
• TLC — Thin-Layer Chromatography
• WHO — World Health Organization

REFERENCES

1. Singh S, Raghav PK: Review on pharmacological properties of Caesalpinia bonduc L. International Journal of Medicinal and Aromatic Plants (2012), 2(3):514–530.
2. Srinivasan P, Karunanithi K, Muniappan A, et al: Botany, traditional usages, phytochemistry, pharmacology, and toxicology of Guilandina bonduc L.: A systematic review. Naunyn-Schmiedeberg's Archives of Pharmacology (2024), 397(5):2747–2775.
3. Ata A, Gale EM and Samarasekera R: Bioactive chemical constituents of Caesalpinia bonduc (Fabaceae). Phytochemistry Letters (2009), 2(3):106–109.
4. Ata A, Udenigwe CC, Gale EM and Samarasekera R: Minor chemical constituents of Caesalpinia bonduc. Natural Product Communications (2009), 4(3):311–314.
5. Sasidharan S, Srinivasa Kumar KP, Kanti Das S and Hareendran Nair J: Caesalpinia bonduc: A ubiquitous yet remarkable tropical plant owing various promising pharmacological and medicinal properties with special references to the seed. Medicinal and Aromatic Plants, Los Angeles (2021), 10(7):394.
6. Ali A, Shalam MD, Ashfaq M, Rao N, Gouda S and Shantakumar S: Anticonvulsive effect of seed extract of Caesalpinia bonducella (Roxb.). Iranian Journal of Pharmacology and Therapeutics (2009), 8:51–55.
7. Archana P, Tandan SK, Chandra S and Lal J: Antipyretic and analgesic activities of Caesalpinia bonducella seed kernel extract. Phytotherapy Research (2005), 19(5):376–381.
8. Arif T, Mandal TK, Kumar N, et al: In vitro and in vivo antimicrobial activities of seeds of Caesalpinia bonduc (Lin.) Roxb. Journal of Ethnopharmacology (2009), 123(1):177–180.
9. Arunadevi R, Tandan SK, Kumar D, Dudhgaonkar SP and Lal J: Analgesic activity of Caesalpinia bonducella flower extract. Pharmaceutical Biology (2008), 46(11):668–672.
10. Gowri M, Lakshmanan H, et al: Ethanolic extract of Caesalpinia bonduc seeds triggers yeast metacaspase-dependent apoptotic pathway mediated by mitochondrial dysfunction through enhanced production of calcium and ROS in Candida albicans. Frontiers in Microbiology (2022), PMC9449877.
11. Sembiring EN, Elya B and Sauriasari R: Phytochemical screening, total flavonoid and total phenolic content, and antioxidant activity of different parts of Caesalpinia bonduc (L.) Roxb. Pharmacognosy Journal (2018), 10(1):123–127.
12. Shanmugapriya A, Jannathul Firdous, Karpagam T, Suganya V and Varalakshmi B: Anti-diabetic and free radical scavenging activity of phytochemicals from Caesalpinia bonducella. International Journal of Advancement in Life Sciences Research (2024), 7(3):166–175.
13. WHO: WHO guidelines on good agricultural and collection practices (GACP) for medicinal plants. World Health Organization, Geneva (2003).
14. Arunadevi R, Murugammal S, Kumar D and Tandan SK: Evaluation of Caesalpinia bonducella flower extract for anti-inflammatory action in rats and its HPTLC fingerprinting. Indian Journal of Pharmacology (2015), 47(6):638–643.
15. World Flora Online: Accepted name: Guilandina bonduc L. (2023) https://wfoplantlist.org/plant-list [accessed January 2025].
16. Trivedi K, Patel V, Parekh A, et al: Preliminary phytochemistry and HPTLC fingerprint profile of leaf extract of Latakaranj: A pharmaceutically significant plant. Research Journal of Pharmacognosy and Phytochemistry (2024), pp. 213–219.
17. Iheagwam FN, et al: Phytochemical identification and antioxidant activity of ethanolic leaf and young twig extracts of Guilandina bonduc L. Journal of Natural Medicines (2019).
18. Pournaghi P, et al: Phytochemical analysis of legume fractions of Caesalpinia bonduc. Food and Chemical Toxicology (2021), 148:111958.
19. Shukla S, Mehta A, Mehta P and Bajpai VK: Antioxidant ability and total phenolic content of aqueous leaf extract of Caesalpinia bonduc (L.) Roxb. Food and Chemical Toxicology (2011), 49(12):3158–3163.
20. Rahman MA, Sultana R, Bin Emran T, et al: Antibacterial, antidiarrhoeal, and cytotoxic activities of methanol extract and its fractions of Caesalpinia bonducella (L.) Roxb leaves. BMC Complementary and Alternative Medicine (2013), 13:101.
21. Iyengar MA and Pendse GS: Antidiarrhoeal activity of the nut of Caesalpinia bonducella Flem. Indian Journal of Pharmacology (1965), 27:307–308.